Assembly Biosciences, Inc. Operating Expenses
Assembly Biosciences, Inc. (ASMB) reported Operating Expenses of $19.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Assembly Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $19.72M, a 4.83% decline year-over-year.
- Assembly Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $19.58M, a 1.15% increase year-over-year.
- Assembly Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $22.67M, a 20.02% increase year-over-year.
- Assembly Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $21.67M, a 21.75% increase year-over-year.
- Assembly Biosciences, Inc. operating expenses for fiscal 2025 was $84.42M, a 14.18% increase from fiscal 2024.
- Assembly Biosciences, Inc. operating expenses for fiscal 2024 was $73.94M, a 2.97% increase from fiscal 2023.
- Assembly Biosciences, Inc. operating expenses for fiscal 2023 was $71.81M, a 23.70% decline from fiscal 2022.
- Assembly Biosciences, Inc. operating expenses for fiscal 2022 was $94.11M, a 32.26% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.72M 10-Q · filed 2026-08-13 | $39.30M 10-Q · filed 2026-08-13 | $61.97M derived: sum of 3 quarters · filed 2026-08-13 | $83.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $19.58M 10-Q · filed 2026-05-07 | $42.25M derived: sum of 2 quarters · filed 2026-05-07 | $63.92M derived: sum of 3 quarters · filed 2026-05-07 | $84.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $22.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $44.34M derived: sum of 2 quarters · filed 2026-03-19 | $65.06M derived: sum of 3 quarters · filed 2026-08-13 | $84.42M 10-K · filed 2026-03-19 |
| 2025-09-30 | $21.67M 10-Q · filed 2025-11-10 | $42.39M derived: sum of 2 quarters · filed 2026-08-13 | $61.75M 10-Q · filed 2025-11-10 | $80.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $20.72M 10-Q · filed 2026-08-13 | $40.08M 10-Q · filed 2026-08-13 | $58.97M derived: sum of 3 quarters · filed 2026-08-13 | $76.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $19.36M 10-Q · filed 2026-05-07 | $38.25M derived: sum of 2 quarters · filed 2026-05-07 | $56.05M derived: sum of 3 quarters · filed 2026-05-07 | $76.79M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $36.69M derived: sum of 2 quarters · filed 2026-03-19 | $57.43M derived: sum of 3 quarters · filed 2026-03-19 | $73.94M 10-K · filed 2026-03-19 |
| 2024-09-30 | $17.80M 10-Q · filed 2025-11-10 | $38.54M derived: sum of 2 quarters · filed 2025-11-10 | $55.05M 10-Q · filed 2025-11-10 | $74.77M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $20.74M 10-Q · filed 2025-08-06 | $37.25M 10-Q · filed 2025-08-06 | $56.96M derived: sum of 3 quarters · filed 2025-08-06 | $72.01M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $16.51M 10-Q · filed 2025-05-08 | $36.23M derived: sum of 2 quarters · filed 2025-05-08 | $51.28M derived: sum of 3 quarters · filed 2025-05-08 | $68.76M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $19.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $34.76M derived: sum of 2 quarters · filed 2025-03-20 | $52.25M derived: sum of 3 quarters · filed 2025-03-20 | $71.81M 10-K · filed 2025-03-20 |
| 2023-09-30 | $15.05M 10-Q · filed 2024-11-07 | $32.54M derived: sum of 2 quarters · filed 2024-11-07 | $52.09M 10-Q · filed 2024-11-07 | $75.07M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $17.49M 10-Q · filed 2024-08-08 | $37.05M 10-Q · filed 2024-08-08 | $60.02M derived: sum of 3 quarters · filed 2024-08-08 | $83.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $19.56M 10-Q · filed 2024-05-08 | $42.54M derived: sum of 2 quarters · filed 2024-05-08 | $65.94M derived: sum of 3 quarters · filed 2024-05-08 | $90.51M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $22.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $46.38M derived: sum of 2 quarters · filed 2024-03-28 | $70.95M derived: sum of 3 quarters · filed 2024-03-28 | $94.11M 10-K · filed 2024-03-28 |
| 2022-09-30 | $23.40M 10-Q · filed 2023-11-08 | $47.97M derived: sum of 2 quarters · filed 2023-11-08 | $71.14M 10-Q · filed 2023-11-08 | $134.03M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $24.57M 10-Q · filed 2023-08-09 | $47.73M 10-Q · filed 2023-08-09 | $110.62M derived: sum of 3 quarters · filed 2023-08-09 | $135.75M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $23.16M 10-Q · filed 2023-05-04 | $86.05M derived: sum of 2 quarters · filed 2023-05-04 | $111.18M derived: sum of 3 quarters · filed 2023-05-04 | $134.85M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $62.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $88.02M derived: sum of 2 quarters · filed 2023-03-22 | $111.68M derived: sum of 3 quarters · filed 2023-03-22 | $138.94M 10-K · filed 2023-03-22 |
| 2021-09-30 | $25.13M 10-Q · filed 2022-11-08 | $48.80M derived: sum of 2 quarters · filed 2022-11-08 | $76.05M 10-Q · filed 2022-11-08 | $116.73M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $23.67M 10-Q · filed 2022-08-09 | $50.92M 10-Q · filed 2022-08-09 | $91.60M derived: sum of 3 quarters · filed 2022-08-09 | $130.23M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $27.26M 10-Q · filed 2022-05-12 | $67.94M derived: sum of 2 quarters · filed 2022-05-12 | $106.57M derived: sum of 3 quarters · filed 2022-05-12 | $139.36M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $40.68M 10-K · filed 2021-02-25 | $79.31M derived: sum of 2 quarters · filed 2021-11-04 | $112.11M derived: sum of 3 quarters · filed 2021-11-04 | $143.88M 10-K · filed 2022-03-11 |
| 2020-09-30 | $38.63M 10-Q · filed 2021-11-04 | $71.43M derived: sum of 2 quarters · filed 2021-11-04 | $103.20M 10-Q · filed 2021-11-04 | $136.65M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $32.80M 10-Q · filed 2021-08-05 | $64.57M 10-Q · filed 2021-08-05 | $98.02M derived: sum of 3 quarters · filed 2021-08-05 | $128.25M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $31.77M 10-Q · filed 2021-05-06 | $65.23M derived: sum of 2 quarters · filed 2021-05-06 | $95.45M derived: sum of 3 quarters · filed 2021-05-06 | $118.23M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $33.45M 10-K · filed 2021-02-25 | $63.67M derived: sum of 2 quarters · filed 2021-02-25 | $86.45M derived: sum of 3 quarters · filed 2021-02-25 | $118.68M 10-K · filed 2021-02-25 |
| 2019-09-30 | $30.22M 10-K · filed 2021-02-25 | $53.00M derived: sum of 2 quarters · filed 2021-02-25 | $85.23M 10-Q · filed 2020-11-05 | $115.28M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $22.78M 10-K · filed 2021-02-25 | $55.00M 10-Q · filed 2020-08-05 | $85.06M derived: sum of 3 quarters · filed 2021-02-25 | $111.92M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $32.22M 10-K · filed 2021-02-25 | $62.28M derived: sum of 2 quarters · filed 2021-02-25 | $89.14M derived: sum of 3 quarters · filed 2021-02-25 | $119.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $30.06M 10-K · filed 2020-03-04 | $56.92M derived: sum of 2 quarters · filed 2020-03-04 | $87.30M derived: sum of 3 quarters · filed 2020-03-04 | $107.54M 10-K · filed 2021-02-25 |
| 2018-09-30 | $26.86M 10-K · filed 2020-03-04 | $57.24M derived: sum of 2 quarters · filed 2020-03-04 | $77.48M derived: sum of 3 quarters · filed 2020-03-04 | |
| 2018-06-30 | $30.38M 10-K · filed 2020-03-04 | $50.62M derived: sum of 2 quarters · filed 2020-03-04 | ||
| 2018-03-31 | $20.24M 10-K · filed 2020-03-04 | |||
| 2017-12-31 | $61.25M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |